Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: A meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wang, Xiwei ^a   Liu, Fen ^a   Wei, Fang ^a   Ren, Hong ^a   Hu, Aidong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; INTERFERON; MACROGOL DERIVATIVE;

ALOPECIA; ANEMIA; ARTICLE; ATTRIBUTABLE RISK; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HYPERTHYROIDISM; INSOMNIA; LEUKOCYTE COUNT; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID VIROLOGICAL RESPONSE; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; CHEMISTRY; GENOTYPE; HEPATITIS C, CHRONIC; SAFETY;

GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; POLYETHYLENE GLYCOLS; RIBAVIRIN; SAFETY;

EID: 84903552268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100128     Document Type: Article

References (42)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
2. Chao DT, Abe K, Nguyen MH (2011) Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 34: 286-296.
3. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, et al. (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 32: 884-892. (Pubitemid 24100056)
4. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, et al. (1995) Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. The Journal of general virology 76 (Pt 5): 1197-1204.
5. Nguyen MH, Keeffe EB (2005) Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 3: S97-S101.
6. Mellor J, Walsh EA, Prescott LE, Jarvis LM, Davidson F, et al. (1996) Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 34: 417-423. (Pubitemid 26035123)
7. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 Suppl 1: i36-46.
8. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
9. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
10. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, et al. (2011) Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 141: 2047-2055; quiz e2014.
11. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, et al. (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
12. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
13. Davis GL, Lau JY (1997) Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26: 122S-127S. (Pubitemid 27388084)
14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965. (Pubitemid 32913521)
15. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999. (Pubitemid 38670134)
16. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, et al. (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28: 397-404. (Pubitemid 352033287)
17. European Association for the Study of the L (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.
18. Freeman MF and Tukey JW (1950) Transformations related to the angular and the square root. The Annals of Mathematical Statistics 21: 607-611.
19. DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Controlled clinical trials 7: 177-188. (Pubitemid 17189972)
20. Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, et al. (2013) Treatment outcomes of treatment-naive Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 8: e55373.
21. Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL (2012) Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clinical and experimental gastroenterology 5: 11-21.
22. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
23. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 315: 629-634. (Pubitemid 27387172)
24. Qing-Xian C, Zhixin Z, Lin C, Min X, Min W, et al. (2013) Shortened treatment duration in treatment-naive genotype 6 chronic hepatitis C patients with rapid virological response: A randomized controlled trial. Hepatology 58: 1098A.
25. Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, et al. (2011) Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 18: 595-600.
26. Tsang OT, Zee JS, Chan JM, Li RS, Kan YM, et al. (2010) Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 25: 766-771.
27. Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K (2012) A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol 56: 1012-1018.
28. Tangkijvanich P, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, et al. (2012) Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. J Viral Hepat 19: 423-430.
29. Shao X, Zhao Z, Cai Q, Zhang X, Gao Z (2012) THE DYNAMIC ANALYSIS OF THE TH1/TH2 RATIO DURING THE INTERFERON ALPHA/RIBAVIRIN COMBINATION THERAPY FOR HCV GENOTYPE 6 INFECTED PATIENTS. Journal of Hepatology 56: S66-S67.
30. Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, et al. (2013) Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. Journal of viral hepatitis 20: 470-477.
31. Nguyen NH, VuTien P, Garcia RT, Trinh H, Nguyen H, et al. (2010) Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 17: 691-697.
32. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, et al. (2008) Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. The American journal of gastroenterology 103: 1131-1135. (Pubitemid 351677993)
33. Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, et al. (2012) Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 50: 441-444.
34. Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, et al. (2010) Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 52: 1573-1580.
35. Fung J, Lai CL, Hung I, Young J, Cheng C, et al. (2008) Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. The Journal of infectious diseases 198: 808-812.
36. Cai Q-X, Zhao Z, Zhang X, Gao Z, Lin C, et al. (2011) THE HIGH IL-28B CC GENOTYPE CONTRIBUTE TO THE GOOD RESPONSE OF CHRONIC HEPATITIS C GENOTYPE 6 IN CHINA. Hepatology 54: 829A-830A.
37. Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, et al. (2013) Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58: 445-451.
38. Lawitz E, Gane EJ (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369: 678-679.
39. Clark VC, Peter JA, Nelson DR (2013) New therapeutic strategies in HCV: second-generation protease inhibitors. Liver international: official journal of the International Association for the Study of the Liver 33 Suppl 1: 80-84.
40. Gerber L, Welzel TM, Zeuzem S (2013) New therapeutic strategies in HCV: polymerase inhibitors. Liver international: official journal of the International Association for the Study of the Liver 33 Suppl 1: 85-92.
41. Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T (2013) Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World journal of hepatology 5: 496-504.
42. Tsang OT, Zee J, Chan J, Li RS, Lai JY, et al. (2008) A RETROSPECTIVE COMPARATIVE STUDY OF PEGYLATED INTERFERON AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 AND GENOTYPE 1. Hepatology 48: 884A-884A.